The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Biomarker Development, 2015Comparison of Pre- and Post-mortem Cerebrospinal Fluid Levels of Proteins and Lipids
Study Rationale:
Alpha-synuclein aggregation in the brain is the main pathology of Parkinson’s disease (PD). Cerebrospinal fluid (CSF) levels of alpha-synuclein are lower in PD. It... -
Dyskinesia Challenge, 2015Biomarkers and Sensors for Levodopa-induced Dyskinesia
Study Rationale:
Levodopa is the gold-standard drug for treatment of Parkinson’s disease (PD), but chronic use is associated with serious motor complications called levodopa-induced... -
Dyskinesia Challenge, 2015Targeting M4 Muscarinic Receptors for the Treatment of Levodopa-induced Dyskinesia
Study Rationale:
Levodopa-induced dyskinesia is thought to stem from sustained stimulation of D1 dopamine receptors (D1Rs). One potential strategy for diminishing excessive D1R... -
Research Grant, 2015Neurorestorative Effects of a Sigma-1 Receptor Agonist in a Model of Parkinson’s Disease
Study Rationale:
In a previous MJFF-sponsored project, we evaluated PRE-084 (an experimental compound binding to the sigma-1 receptor) in pre-clinical models of Parkinson’s disease... -
Research Grant, 2015Development of a Radioligand for Imaging of Alpha-synuclein with Positron Emission Tomography
Study Rationale:
The visualization of alpha-synuclein deposition in the living human brain is of high need as a biomarker for Parkinson´s disease (PD). Positron emission tomography... -
Target Validation, 2015Synapsin III: A Novel Therapeutic Target for Parkinson’s Disease
Objective/Rationale:
In Parkinson’s disease (PD) accumulation of alpha-synuclein at striatal synapses, the neuronal sites of dopamine release, is believed to trigger cell degeneration. We have found...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.